A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Carcinoma, Hepatocellular
  • Liver Neoplasms

abstract

  • Cixutumumab monotherapy did not have clinically meaningful activity in this unselected HCC population. Grade 3-4 hyperglycemia occurred in 46% of patients. Elevated IGFBP-1 correlated with improved PFS and OS.

publication date

  • February 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3901953

Digital Object Identifier (DOI)

  • 10.1016/j.jhep.2013.09.008

PubMed ID

  • 24045151

Additional Document Info

start page

  • 319

end page

  • 24

volume

  • 60

number

  • 2